A Phase 1/2a First-In-Human Study of BMS-986218 (CTL NF) A Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Study of Drug Alone and In Combination with Nivolumab in Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAR2426
U.S. Govt. ID: NCT03110107
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test the safety of an investigational study drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody) administered alone and in combination with nivolumab, and in comparison to Ipilimumab. This study will investigate how research subjects with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose of BMS-986218 alone and in combination with nivolumab, in cancer research subjects. This is the first study in which BMS-986218 will be administered to humans. Nivolumab and ipilimumab have been administered to and is approved for human use in multiple tumor types.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with advanced solid tumor? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator